

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934.**

**Date of Report: May 5, 2008  
(Date of earliest event reported)**

---

**Oragenics, Inc**

(Exact name of registrant as specified in its charter)

---

**FL**  
(State or other jurisdiction  
of incorporation)

**001-32188**  
(Commission File Number)

**59-3410522**  
(IRS Employer  
Identification Number)

**13700 Progress Blvd**  
(Address of principal executive offices)

**32615**  
(Zip Code)

**386-418-4018**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 OTHER EVENTS**

On May 13, 2008, Oragenics, Inc. (the “Company”) issued a press release regarding the Company’s expected name change to “ONI BioPharma Inc.” and the use of the Company’s new name “ONI BioPharma Inc.” until the name change can be formally approved by shareholders. The press release is attached to this report as Exhibit 99.1 and incorporated by reference herein.

**Item 9.01 FINANCIAL INFORMATION AND EXHIBITS****(c) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated May 13, 2008

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 13<sup>th</sup> day of May, 2008.

**ORAGENICS, INC.**  
**(Registrant)**

BY: /s/ Stanley Stein

Stanley Stein  
President and Chief Executive Officer

**Orogenics, Inc. Changes Name to ONI Biopharma Inc.****FOR IMMEDIATE RELEASE**

**ALACHUA, FL (May 13, 2008)** – Orogenics, Inc. (AMEX:ONI) announced today that its Board of Directors approved the use of the Company's new name of ONI BioPharma Inc. The Company recently registered in the State of Florida to do business as "ONI BioPharma Inc." The Company will refer to itself as ONI BioPharma from this point forward and expects to seek to obtain shareholder approval to amend its articles of incorporation in order to formally change its name from Orogenics, Inc. to ONI BioPharma Inc. in connection with the next annual meeting of shareholders. The Company believes that the new name more accurately reflects the broad range of scientific platforms and products that the Company has under development through the efforts of its scientific team, headed by Dr. Jeffrey Hillman, our Chief Scientific Officer.

Our Chairman, Richard T. Welch, stated that, "although we remain committed to oral health, the Company is active in the development of novel antibiotics and diagnostics as well and the new 'doing business name,' ONI BioPharma, conveys a better sense of a company that is active in other areas, in particular the infectious diseases arena."

Notwithstanding our doing business as ONI BioPharma Inc, and our expected future formal name change, our common stock will continue to trade under the stock symbol "ONI" on the American Stock Exchange.

**About Orogenics**

Orogenics, Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases. Our core pipeline includes products and supporting platform technologies for use in the treatment and diagnosis of bacterial infections.

*Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Orogenics Inc.'s (d/b/a ONI BioPharma) current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

**Contact:**

Orogenics, Inc.  
Stanley B. Stein, 386-418-4018 X222  
[www.orogenics.com](http://www.orogenics.com)

###